Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well a positron emission tomography (PET)/computed tomography
(CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning
radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.
Fluciclovine F18 and 68Ga-PSMA are types of tracers, called radiotracers, that are injected
and can accumulate in tumor cells to develop images of them during a PET/CT scan. It is not
yet known whether giving fluciclovine F18 or 68Ga-PSMA may work better in planning radiation
treatments and enhancing outcomes in patients with prostate adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
National Cancer Institute (NCI) Telix International Pty Ltd